Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
390.00    0.00 (0.00%)
Bid:
385.00
Ask:
395.00
Spread: 10.00 (2.597%)
Market Cap: £187.19m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Directorate Change

2 Jun 2010 07:00

RNS Number : 9010M
Tristel PLC
02 June 2010
 



 

("Tristel" or the "Company")

AIM: TSTL

 

Board Changes

 

Tristel plc, the AIM listed provider of infection and contamination control products, announces the appointment of Elizabeth Dixon as finance director. Ms Dixon replaces Paul Barnes who has been part-time group finance director since before the Company's flotation in June 2005. Mr Barnes continues on the Board as non-executive chairman of the Audit Committee. 

 

Ms Dixon, aged 40, is an experienced financial and management accountant having held senior finance roles for the past 10 years. She has acted as Tristel's group chief accountant since July 2007 and was appointed as finance director of the main trading subsidiary Tristel Solutions Limited in August 2009.

 

Ms Dixon is currently interested in 1,009 Ordinary 1p Shares, representing less than 1 per cent of the Company's issued share capital. In addition she holds options over 120,000 ordinary shares of 1p each in the Company ("Shares") under the Tristel plc Enterprise Management Incentive Scheme 2005 (the "Scheme"). 45,000 of these options are currently exercisable at 53.75p per share, further tranches of 15,000 options are exercisable at 53.75p on each of the following dates, 23rd July 2010, 4th August 2010, 23rd July 2011, 4th August 2011 and 4th August 2012

 

Pursuant to Rule 17, Schedule Two (g) of the AIM Rules for Companies the following information is disclosed:

 

Current Appointments of Elizabeth Dixon

Tristel Solutions Limited

 

Previous Appointments

None

 

ENDS

 

For further information, please contact:

Tristel PLC

 

Paul Swinney, Chief Executive

Tel: 01638 721 500

 

 

Walbrook PR Ltd

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

 

paul.mcmanus@walbrookpr.com

 

 

FinnCap

 

Geoff Nash/Rhydian Bankes (Corporate Finance)

Tel: 020 7600 1658

Simon Starr (Corporate Broking)

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAEAXKFELLEEFF
Date   Source Headline
2nd Oct 202311:50 amRNSHolding(s) in Company
28th Sep 20232:00 pmRNSExercise of Share Options and Total Voting Rights
26th Sep 20232:40 pmRNSHolding(s) in Company
25th Sep 20238:40 amRNSHolding(s) in Company
22nd Sep 20233:40 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
4th Sep 20237:00 amRNSHealth Canada regulatory approval submission
31st Jul 20238:05 amRNSHolding(s) in Company
28th Jul 20238:28 amRNSDirector/PDMR Shareholding
25th Jul 20237:00 amRNSTrading update
12th Jul 20237:00 amRNSShareholder Open Day and Notice of Trading Update
10th Jul 20237:00 amRNSExercise of Share Options and Total Voting Rights
26th Jun 20237:00 amRNSDirector/PDMR Shareholding
22nd Jun 20234:01 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSExercise of Share Options and Total Voting Rights
14th Jun 20234:10 pmRNSHolding(s) in Company
6th Jun 20235:00 pmRNSExercise of Share Options and Total Voting Rights
5th Jun 202310:00 amRNSAnalyst and Investor presentation
5th Jun 20237:00 amRNSFDA De Novo approval
28th Mar 202311:30 amRNSIssue of Equity
27th Mar 20237:00 amRNSSuccessful submission of additional data to US FDA
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 20239:30 amRNSIssue of Equity
22nd Feb 20234:30 pmRNSIssue of Equity
20th Feb 20237:00 amRNSHalf-year Report
30th Jan 20237:00 amRNSNotice of Results and Investor presentation
14th Dec 202211:00 amRNSResult of AGM - Replacement
13th Dec 20227:00 amRNSIssue of Equity
12th Dec 202211:26 amRNSResult of AGM
12th Dec 20227:00 amRNSAGM Statement
2nd Nov 20221:50 pmRNSHolding(s) in Company
25th Oct 20227:00 amRNSAudited Preliminary Results
6th Oct 20229:15 amRNSIssue of Equity
4th Oct 202212:00 pmRNSAppointment of new Company Secretary
4th Oct 20227:00 amRNSNotice of Results & Investor Presentation
29th Sep 20221:00 pmRNSNorth America update
30th Aug 20227:00 amRNSHolding(s) in Company
22nd Jul 20221:05 pmRNSDirector/PDMR Shareholding
21st Jul 202210:15 amRNSHolding(s) in Company
18th Jul 20224:41 pmRNSSecond Price Monitoring Extn
18th Jul 20224:35 pmRNSPrice Monitoring Extension
18th Jul 20227:00 amRNSTrading update and special dividend
30th Jun 20227:00 amRNSDe Novo FDA submission for Tristel Duo ULT
20th Jun 202210:00 amRNSShareholder Open Day & Notice of Trading update
7th Jun 20221:15 pmRNSHolding(s) in Company
4th May 20227:00 amRNSInvestor Presentation
3rd May 202212:30 pmRNSHolding(s) in Company
14th Apr 202212:00 pmRNSIssue of Equity
6th Apr 202212:10 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.